Clinical evidence for high-risk medical devices used to manage diabetes: protocol for a systematic review and meta-analysis

Arjola Bano, Markus Laimer, Faina Wehrli, Juri Kunzler, Tania Rivero, Alan G Fraser, Christoph Stettler, Roman Hovorka, Lia Bally

ABSTRACT

Introduction Medical devices, including high-risk medical devices, have greatly contributed to recent improvements in the management of diabetes. However, the clinical evidence that is submitted for regulatory approval is not transparent, and thus a comprehensive summary of the evidence for high-risk devices approved for managing diabetes in Europe is lacking. In the framework of the Coordinating Research and Evidence for Medical Devices group, we will, therefore, perform a systematic review and meta-analysis, which will evaluate the efficacy, safety and usability of high-risk medical devices for the management of diabetes.

Method and analysis This study has been reported according to the guidelines of the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols. We will search Embase (Elsevier), Medline All (Ovid), Cochrane Library (Wiley), Science Citation Index Expanded and Emerging Sources Citation Index (Web of Science) to identify interventional and observational studies that evaluate the efficacy and/or safety and/or usability of high-risk medical devices for the management of diabetes. No language or publication dates’ limits will be applied. Animal studies will be excluded. In accordance with the Medical Device Regulation in European Union, high-risk medical devices are those in classes IIb and III. The following medical devices for diabetes management are considered as having a high risk: implantable continuous glucose monitoring systems, implantable pumps and automated insulin delivery devices. Selection of studies, data extraction and quality of evidence assessment will be performed independently by two researchers. Sensitivity analysis will be performed to identify and explain potential heterogeneity.

Ethics and dissemination No ethical approval is needed for this systematic review, as it is based in already published data. Our findings will be published in a peer-reviewed journal.

PROSPERO registration number CRD42022366871.

INTRODUCTION

The classification of medical devices in the European Union applies a risk-based system that takes account of the vulnerability of the human body and the potential risks associated with the devices. High-risk medical devices in class IIb or III according to the new Medical Device Regulation (MDR; EU 2017/745) include devices and software that support or sustain human life or prevent impairment of human health but, when used, pose high risks to patients (serious deterioration of health, irreversible deterioration of health or death). During recent decades, the management of diabetes has changed profoundly and the ability to control glucose levels has improved significantly. The development of several medical devices has greatly contributed to this progress. Some of the devices belong to the high-risk category as they either involve automated drug delivery or implanted components.

To date, the clinical evidence that is submitted for regulatory approval is not transparent, and thus a comprehensive summary of the evidence on the efficacy, safety and usability of high-risk medical devices approved for managing diabetes in Europe is lacking. In the framework of the Coordinating Research and Evidence for Medical Devices group, we will review the literature on high-risk medical devices for diabetes monitoring and treatment before and after the CE mark approval. Toward this end, we will conduct a systematic review and meta-analysis to assess whether high-risk medical devices for diabetes...
management are useful, safe and effective. We will review study designs, statistical methods, reported outcomes and overall quality of evidence. If possible, we will consider additionally stratifying by sex, age and other patient characteristics. Generated insights shall contribute to greater transparency in the field of high-risk medical devices for diabetes monitoring and treatment, by presenting available treatment modalities and exchanging information pertaining to their efficacy, safety and usability profiles to support decisions and recommendations.7

High-risk medical devices for diabetes management

The MDR specifies a number of criteria to define high-risk medical devices (classes IIb and III). Among others, all implantable devices and long-term surgically invasive devices are in class III if they are intended: (a) to have a biological effect; (b) to be wholly or mainly absorbed; (c) to undergo chemical change in the body (except if the devices are placed in the teeth) or (d) to administer medicines (Rule 8, medical device regulations).1 All devices incorporating, as an integral part, a substance which, if used separately, can be considered to be a medicinal product, and which is liable to act on the human body with action ancillary to that of the devices, are in class III (Rule 13, medical device regulations).1 Software intended to provide information which is used to take decisions with diagnosis or therapeutic purposes is classified as class III medical device if such decisions have an impact that may cause death or an irreversible deterioration of a person’s state of health and is classified as class IIb if such decisions have an impact that may cause serious deterioration of a person’s state of health (Rule 11, medical device regulations).1 Active therapeutic devices with an integrated or incorporated diagnostic function which significantly determines the patient management by the device, such as closed loop systems, are classified as class III (Rule 22, medical device regulations).1 Applying these criteria to the field of diabetes, we consider the following medical devices as having a high risk:

► Implantable continuous glucose monitoring systems.
► Implantable pumps (regardless of mode of insulin delivery).
► Automated insulin delivery devices (software as a medical device): herein, we will exclude sensor-augmented insulin pumps with low glucose threshold suspend and predictive low glucose suspend features.

These devices represent a special case for high-risk devices because they incorporate components for monitoring glucose levels, which if standalone would qualify as in vitro diagnostic devices, combined with external and internally implanted hardware, and drug delivery systems driven by control algorithms.

Given the current lack of a complete and fully functional database with registered CE-marked devices, we will attempt to identify information on manufacturers, authorised representatives, notified bodies, date of certification and vigilance data for each device through: (a) press releases available online or scientific publications mentioning the date of CE marking; (b) contacting the device manufacturers and (c) national databases of European Regulatory Authorities or other stakeholders. We will also consult European Database on Medical Devices database with the knowledge that registration of medical devices is not mandatory yet.8 A draft list of eligible medical devices in the field of diabetes is provided in table 1.

Table 1 Draft list of eligible medical devices in the field of diabetes

<table>
<thead>
<tr>
<th>Class of device</th>
<th>Device</th>
<th>Manufacturer</th>
<th>CE mark approval date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Implantable CGM devices</td>
<td>Implantable Eversense CGM sensor</td>
<td>Senseonics Inc.</td>
<td>2016</td>
</tr>
<tr>
<td>Implantable insulin pumps</td>
<td>MiniMed MIP2007C</td>
<td>Medtronic</td>
<td>2013</td>
</tr>
<tr>
<td></td>
<td>Diaport</td>
<td>Roche</td>
<td>2012</td>
</tr>
<tr>
<td>Automated insulin delivery devices</td>
<td>Hybrid closed-loop systems</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MiniMed 670G</td>
<td>Medtronic</td>
<td>2018</td>
</tr>
<tr>
<td></td>
<td>MiniMed 780 G</td>
<td>Medtronic</td>
<td>2020</td>
</tr>
<tr>
<td></td>
<td>Control-IQ</td>
<td>Tandem Diabetes Care</td>
<td>2020</td>
</tr>
<tr>
<td></td>
<td>DBLG1</td>
<td>Diabeloop</td>
<td>2018</td>
</tr>
<tr>
<td></td>
<td>Inreda AP</td>
<td>Inreda Diabetic</td>
<td>2016</td>
</tr>
<tr>
<td></td>
<td>Tidepool Loop</td>
<td>Tidepool</td>
<td>Pending</td>
</tr>
<tr>
<td></td>
<td>Omnispod 5 system</td>
<td>Insulet</td>
<td>2022</td>
</tr>
<tr>
<td></td>
<td>iLet Bionic Pancreas System</td>
<td>Medtech Beta Bionics</td>
<td>Pending</td>
</tr>
<tr>
<td></td>
<td>CamAPS FX</td>
<td>CamDiab</td>
<td>2020</td>
</tr>
<tr>
<td></td>
<td>CamAPS HX</td>
<td>CamDiab</td>
<td>2020*</td>
</tr>
</tbody>
</table>

*CE mark approval but not commercially available CGM, continuous glucose monitoring.
METHODS AND ANALYSIS

Study protocol

The current protocol has been registered in PROSPERO (CRD42022368571) and has been reported using the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols Guidelines (online supplemental material 1). We will consult the Cochrane Collaboration Handbook to perform our systematic review. The systematic review will be reported in accordance with the PRISMA 2020 guidelines for transparent reporting.

Searches

An expert medical librarian carried out the literature searches. A variety of databases including Embase (Elsevier), Medline All (Ovid), Cochrane Library (Wiley), Science Citation Index Expanded and Emerging Sources Citation Index (Web of Science) were searched from inception to 2022 (online supplemental material 2). The search strategy consists of controlled vocabulary terms (eg, MeSH and EMTREE) and free text terms for the following main elements: (a) diabetes and hyperglycaemia, (b) device-sensitive search algorithms and (c) study design. Study design search filters were adapted and applied to the search strategies. Animal studies were excluded. No language or publication dates limits were applied. Search strategies were translated accordingly for each information source. Grey literature sources were not searched. Prior to the formal abstract screening, a pilot phase between the reviewers was carried out to ensure adequate comprehension and high inter-rater reliability. The final search strategy is presented in online supplemental material 2.

Eligibility criteria

Inclusion criteria

We will include published clinical investigations:

- Participants/population: subjects with hyperglycaemia or diabetes.
- Intervention/exposure: high-risk medical devices for diabetes management.
- Comparator(s)/control: any or no comparator.
- Outcomes: outcomes related to the efficacy, safety, and usability of medical devices.

Outcomes include:

- Efficacy
  - Metrics of glucose control which include glycated haemoglobin (reflecting average blood glucose concentrations for the past 2–3 months) as well as metrics calculated from blood glucose or interstitial glucose concentrations (eg, proportion of values within, above and below range), according to a recently published international consensus statement; acute and chronic glucose-related complications.

- Safety
  - Severe hypoglycaemia and diabetic ketoacidosis.
  - Device-related serious adverse events.
  - Device deficiencies (eg, malfunction, misuse and inadequate labelling).
  - Field safety notices.

- Usability
  - Objective usability (technical performance, eg, % time device was operational).
  - Perceived usability (eg, technology acceptance, ease of use and perceived usefulness).
  - Patient-reported outcome measures for devices used for disease self-management (eg, INSPIRE measures and measures of quality of life, fear of hypoglycaemia and diabetes distress).

Study selection and data extraction

Search results from database searches will be exported to EndNote (V.20) citation management tool. Search results will be de-duplicated in EndNote (V.20), and imported to the Rayyan screening software for title/abstract and full text screening. Two independent reviewers will screen the titles and abstracts of the studies retrieved during the searches, and the full text articles of identified articles will be obtained and fully evaluated. Any disagreements regarding inclusion will be resolved through consensus. In case of disagreement, a third independent reviewer will be consulted. The full texts and reference lists of the selected articles will also be hand searched in order to identify additional studies for inclusion. Abstracts and articles written in a language not spoken by the authors will be translated with the help of an online translator tool (eg, DeepL). Data extraction will be performed for each study using a predesigned data collection form.
In particular, the following PICO components will be extracted from each study.

Population/study
- Journal, first author name, year of publication and funding sources (industry-related/non-industry-related/both/none declared).
- Study design, including observational or experimental; prospective or retrospective and outpatient or inpatient or supervised environments (clinical research facilities, hotels and diabetes camps).
- Recruitment period and follow-up duration.
- Sample size of the study and demographics of study participants.

Intervention
- Product name.
- Manufacturer.
- Date of CE mark approval if available.
- CE mark number and name of the notified body if available.

Comparator
- Medical therapy/standard care.
- Devices, drug-delivery devices, non-drug treatments.
- Sham procedure.
- No intervention.

Outcome
In each study, we will specify the outcome of interest, the outcome measure and the time-point of the assessment during follow-up. We will also record whether sex or age-specific subgroups analyses are performed.

Risk of bias assessment of included studies
The quality of the included studies will be assessed separately by two reviewers. We will use the Newcastle-Ottawa Scale (NOS) for observational studies. The NOS scale evaluates the study quality based on three domains, namely, the selection of participants, the comparability of study groups and the ascertainment of the outcomes of interest. Each study can be awarded a maximum of nine stars. We will assess the quality of interventional studies using a revised tool for assessing the risk of bias in randomised trials (RoB 2) and a tool for assessing the risk of bias in non-randomised studies of interventions (ROBINS-I). The strength of the overall quality of the evidence will be evaluated using the Grading of Recommendations Assessment, Development and Evaluation scale.

Strategy for data synthesis
We will provide a narrative synthesis of the findings of the included studies. Effect estimates will be reported in a summary table. Using descriptive statistics, we will report study characteristics, type of interventions and results for each device. We will assess potential differences across different study designs (ie, observational studies vs randomised trials), across different classes of devices, and across different products in the same class of device. We will assess characteristics of the clinical studies that were available prior to the market release (CE marking) of the device and the evidence obtained post-market approval. If applicable, we will evaluate whether there are differences in the results when comparing men versus women, and younger versus older populations. The studies will be ordered by ascending year and we will evaluate whether the earliest published studies report sex or age differences more often than the subsequently published studies. For comparisons between categorical variables, we will use the $\chi^2$ test, or Fisher’s exact test, as appropriate. The data will be quantitatively synthesised if at least two studies report effect estimates on a particular medical device and a particular outcome that are sufficiently homogenous for meta-analysis. If a meta-analysis is possible, the effect estimates will be pooled using random effects models, and forest plots will be constructed. Heterogeneity will be assessed by using the $I^2$ statistic according to the most recent version of the Cochrane Handbook: 0%–40%: might not be important; 30%–60%: may represent moderate heterogeneity; 50%–90%: may represent substantial heterogeneity and 75%–100%: considerable heterogeneity. We will also perform ‘leave-one out analysis’ in order to evaluate the impact of individual studies on the overall results. The possibility of publication bias will be examined using funnel plots and Egger’s test. The statistical analyses will be performed in Stata V.15.1 (StataCorp LLC, TX, USA).

Patient and public involvement
None.

Ethics and dissemination
No ethical approval is needed for this systematic review, as it is based on already published data. Our findings will be published in a peer-reviewed journal. The systematic review is now in progress; the data extraction is scheduled to have started in February 2023, and the expected end time is October 2023.

Author affiliations
1Department of Cardiology, Inselspital, Bern University Hospital, Bern, Switzerland
2Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
3Department of Diabetes, Endocrinology, Nutritional Medicine, and Metabolism, Inselspital, Bern University Hospital and University of Bern, Switzerland
4Medical Library, University Library of Bern, University of Bern, Bern, Switzerland
5Department of Cardiology, University Hospital of Wales, Cardiff, UK
6Wellcome Trust, MRC Institute of Metabolic Science, Addenbrooke’s Hospital, Cambridge, UK

Collaborators
On behalf of Coordinating Research and Evidence for Medical Device investigators (see Appendix).

Contributors
AB and LB designed the study and drafted the study protocol. AB, TR and LB contributed to the preparation of the search strategy. AB, ML, FW, JK, TR, AGF, CS, RH and LB revised the protocol critically for important intellectual content. All authors read and approved the final study protocol. AB, ML and LB will be the guarantors of the review.

Funding
This work is supported by a grant from the European Union (CORE MD, Grant Agreement 965246).

Competing interests
RH reports having received speaker honoraria from Eli Lilly, Dexcom and Novo Nordisk, receiving license fees from BBraun, and being director at CamDiab. All other authors declare no competing interests.
Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Ethics approval Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation or adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use and license are distributed in accordance with the terms of the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license.

ORCID iDs
Arjola Bano http://orcid.org/0000-0003-0956-7145
Lia Bally http://orcid.org/0000-0003-1993-7672

REFERENCES


15 Da Oet al. The newcastle-ottawa scale (nos) for assessing the quality of nonrandomised studies in meta-analyses. 2000.


